Phase III study of ST-HT for common cold

An open-label, single-group, multi-center, Phase III study to evaluate the efficacy and safety of ST-HT when administered 3 times daily for 3 days to the patients with common cold

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1080224940

Enrollment

158

Registered

2019-11-08

Start date

2019-10-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Common cold

Interventions

investigational material(s) Generic name etc : ST-HT INN of investigational material : - Therapeutic category code : 1-- Agents affecting nervous system and sensory organs Dosage and Administration fo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Common cold patient diagnosed by the invetigator 2. age: 15 years old and above at the time of giving consent 3. Patient who gives written consent etc.

Exclusion criteria

Exclusion criteria: 1. Patinet who was diagnosed as influenza by the investigator 2. Patient with underlying chronic upper airway disease or lowe ariway disease 3. Patine with seasonal nasal allergy during taking the study medication etc.

Design outcomes

Primary

Measure	Time frame
efficacy Overall improvement	—

Secondary

Measure	Time frame
safety efficacy Score of improvement by symptoms Overall safety	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026